Top-Rated StocksTop-RatedNASDAQ:CYTK Cytokinetics (CYTK) Stock Price, News & Analysis → RSVP: Charles Payne’s Cash Flow Workshop (From Unstoppable Prosperity) (Ad) Free CYTK Stock Alerts $63.12 -0.90 (-1.41%) (As of 03:09 PM ET) Add Compare Share Share Today's Range$61.25▼$64.6150-Day Range$61.32▼$75.0552-Week Range$25.98▼$110.25Volume692,537 shsAverage Volume2.72 million shsMarket Capitalization$6.60 billionP/E RatioN/ADividend YieldN/APrice Target$81.60 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Cytokinetics alerts: Email Address Cytokinetics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.87 Rating ScoreUpside/Downside31.7% Upside$81.60 Price TargetShort InterestBearish13.51% of Float Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment0.24Based on 30 Articles This WeekInsider TradingSelling Shares$6.70 M Sold Last QuarterProj. Earnings GrowthGrowingFrom ($4.50) to ($3.28) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.26 out of 5 starsMedical Sector278th out of 915 stocksPharmaceutical Preparations Industry119th out of 426 stocks 4.4 Analyst's Opinion Consensus RatingCytokinetics has received a consensus rating of Moderate Buy. The company's average rating score is 2.87, and is based on 13 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageCytokinetics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Cytokinetics' stock forecast and price target. Previous Next 2.0 Short Interest Percentage of Shares Shorted13.51% of the float of Cytokinetics has been sold short.Short Interest Ratio / Days to CoverCytokinetics has a short interest ratio ("days to cover") of 7.2.Change versus previous monthShort interest in Cytokinetics has recently decreased by 2.64%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCytokinetics does not currently pay a dividend.Dividend GrowthCytokinetics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCytokinetics has received a 71.40% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Preclinical research services for physical health", "Clinical research services for physiological diseases ", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Cytokinetics is -0.83. Previous Next 1.8 News and Social Media Coverage News SentimentCytokinetics has a news sentiment score of 0.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 30 news articles for Cytokinetics this week, compared to 7 articles on an average week.Search InterestOnly 3 people have searched for CYTK on MarketBeat in the last 30 days. This is a decrease of -77% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Cytokinetics to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 0.8 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cytokinetics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,701,940.00 in company stock.Percentage Held by InsidersOnly 3.40% of the stock of Cytokinetics is held by insiders.Read more about Cytokinetics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cytokinetics are expected to grow in the coming year, from ($4.50) to ($3.28) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cytokinetics is -11.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cytokinetics is -11.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cytokinetics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Banyan Hill PublishingThe Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.See how you can invest alongside him About Cytokinetics Stock (NASDAQ:CYTK)Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Read More CYTK Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CYTK Stock News HeadlinesMay 8, 2024 | insidertrades.comFady Ibraham Malik Sells 15,547 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockApril 26, 2024 | insidertrades.comJohn T. Henderson Sells 10,562 Shares of Cytokinetics, Incorporated (NASDAQ:CYTK) StockMay 10, 2024 | Weiss Ratings (Ad)The ONE AI Stock to own now. (It’s not Nvidia.)Don’t panic — you haven’t missed the boat on AI. In fact, it has barely launched. Sure, the early stages of this boom were big … But I believe the real wealth in AI has yet to be made …April 10, 2024 | insidertrades.comCytokinetics, Incorporated (NASDAQ:CYTK) EVP Sells $2,422,877.55 in StockMay 10, 2024 | finance.yahoo.comCytokinetics First Quarter 2024 Earnings: Misses ExpectationsMay 10, 2024 | markets.businessinsider.comCytokinetics: Buy Rating Affirmed Amid Clinical Advancements and Strategic Regulatory PlansMay 9, 2024 | markets.businessinsider.comCytokinetics: Strong Buy Rating on Promising Aficamten Prospects and Market PotentialMay 9, 2024 | markets.businessinsider.comBuy Rating Affirmed for Cytokinetics Amid Promising Phase 3 Trial Results and Strategic FDA EngagementsMay 10, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.May 9, 2024 | markets.businessinsider.comBuy Rating Affirmed on Cytokinetics’ Aficamten Ahead of Key Phase 3 Study ResultsMay 9, 2024 | markets.businessinsider.comBarclays Keeps Their Buy Rating on Cytokinetics (CYTK)May 9, 2024 | finance.yahoo.comCytokinetics Inc (CYTK) Q1 2024 Earnings Call Transcript Highlights: Navigating Through ...May 9, 2024 | finance.yahoo.comCytokinetics, Incorporated (NASDAQ:CYTK) Q1 2024 Earnings Call TranscriptMay 8, 2024 | investorplace.comCYTK Stock Earnings: Cytokinetics Misses EPS, Misses Revenue for Q1 2024May 8, 2024 | finanznachrichten.deCytokinetics, Incorporated: Cytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586May 8, 2024 | globenewswire.comCytokinetics Reports First Quarter 2024 Financial ResultsMay 8, 2024 | globenewswire.comCytokinetics Announces Topline Data From Phase 1 Clinical Study of CK-4021586May 8, 2024 | globenewswire.comCytokinetics Announces Start of CEDAR-HCM, a Clinical Trial of Aficamten in a Pediatric Population With Symptomatic Obstructive Hypertrophic CardiomyopathyMay 8, 2024 | americanbankingnews.comCytokinetics, Incorporated (NASDAQ:CYTK) EVP Fady Ibraham Malik Sells 15,547 Shares of StockMay 8, 2024 | finance.yahoo.comInsider Sale at Cytokinetics Inc (CYTK): EVP Research & Development Fady Malik Sells SharesMay 7, 2024 | globenewswire.comCytokinetics to Hold Annual Meeting of StockholdersMay 7, 2024 | investorplace.comBiotech Breakthroughs: 7 Stocks Driving the Next Wave in HealthcareMay 2, 2024 | globenewswire.comCytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 2, 2024 | americanbankingnews.comCytokinetics, Incorporated (NASDAQ:CYTK) Short Interest Up 6.1% in AprilMay 1, 2024 | benzinga.com(CYTK) - Analyzing Cytokinetics's Short InterestApril 29, 2024 | globenewswire.comCytokinetics to Host Investor Event and Conference Call to Discuss the Primary Results From SEQUOIA-HCM at the European Society of Cardiology Heart Failure 2024 CongressApril 28, 2024 | barrons.comCytokinetics Inc.See More Headlines Receive CYTK Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cytokinetics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today5/10/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:CYTK CUSIPN/A CIK1061983 Webwww.cytokinetics.com Phone(650) 624-3000Fax650-624-3010Employees423Year Founded1997Price Target and Rating Average Stock Price Target$81.60 High Stock Price Target$108.00 Low Stock Price Target$50.00 Potential Upside/Downside+29.9%Consensus RatingModerate Buy Rating Score (0-4)2.87 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($5.45) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-526,240,000.00 Net Margins-6,988.63% Pretax Margin-6,988.63% Return on EquityN/A Return on Assets-65.08% Debt Debt-to-Equity RatioN/A Current Ratio6.12 Quick Ratio6.12 Sales & Book Value Annual Sales$7.53 million Price / Sales872.61 Cash FlowN/A Price / Cash FlowN/A Book Value($3.94) per share Price / Book-15.95Miscellaneous Outstanding Shares104,580,000Free Float101,020,000Market Cap$6.57 billion OptionableOptionable Beta0.72 Social Links (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Robert I. Blum (Age 60)CEO, President, Principal Financial Officer & Director Comp: $1.33MMr. Robert C. Wong (Age 56)VP & Chief Accounting Officer Comp: $495.72kDr. Fady Ibraham Malik FACC (Age 60)M.D., Ph.D., Executive Vice President of Research & Development Comp: $839.66kMr. Andrew M. Callos (Age 55)Executive VP & Chief Commercial Officer Comp: $752.84kDr. James A. Spudich Ph.D. (Age 82)Co-Founder & Member of Scientific Advisory Board Comp: $21.94kMr. Jeff LotzVice President of Sales & OperationsMr. Matt YangVice President of Corporate Finance and Financial Planning & AnalysisMr. Steven M. Cook (Age 65)Senior Vice President of Global Supply Chain Operations & Technical Operations Ms. Kari K. Loeser J.D.VP & Chief Compliance OfficerMr. John O. Faurescu Esq.VP, Associate General Counsel & Corporate SecretaryMore ExecutivesKey CompetitorsIntra-Cellular TherapiesNASDAQ:ITCIJazz PharmaceuticalsNASDAQ:JAZZElanco Animal HealthNYSE:ELANBlueprint MedicinesNASDAQ:BPMCCerevel TherapeuticsNASDAQ:CEREView All CompetitorsInsiders & InstitutionsState Board of Administration of Florida Retirement SystemSold 940 shares on 5/9/2024Ownership: 0.025%XR Securities LLCBought 18,200 shares on 5/9/2024Ownership: 0.000%ProShare Advisors LLCBought 5,313 shares on 5/8/2024Ownership: 0.028%US Bancorp DEBought 2,265 shares on 5/8/2024Ownership: 0.005%Inspire Investing LLCBought 605 shares on 5/8/2024Ownership: 0.005%View All Insider TransactionsView All Institutional Transactions CYTK Stock Analysis - Frequently Asked Questions Should I buy or sell Cytokinetics stock right now? 15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytokinetics in the last year. There are currently 2 hold ratings and 13 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CYTK shares. View CYTK analyst ratings or view top-rated stocks. What is Cytokinetics' stock price target for 2024? 15 brokerages have issued 1 year target prices for Cytokinetics' shares. Their CYTK share price targets range from $50.00 to $108.00. On average, they predict the company's share price to reach $81.60 in the next year. This suggests a possible upside of 31.7% from the stock's current price. View analysts price targets for CYTK or view top-rated stocks among Wall Street analysts. How have CYTK shares performed in 2024? Cytokinetics' stock was trading at $83.49 at the start of the year. Since then, CYTK stock has decreased by 25.8% and is now trading at $61.98. View the best growth stocks for 2024 here. Are investors shorting Cytokinetics? Cytokinetics saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 14,040,000 shares, an increase of 6.1% from the March 31st total of 13,230,000 shares. Based on an average daily trading volume, of 2,030,000 shares, the days-to-cover ratio is presently 6.9 days. Currently, 13.9% of the company's stock are short sold. View Cytokinetics' Short Interest. When is Cytokinetics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 1st 2024. View our CYTK earnings forecast. How were Cytokinetics' earnings last quarter? Cytokinetics, Incorporated (NASDAQ:CYTK) announced its quarterly earnings results on Wednesday, May, 8th. The biopharmaceutical company reported ($1.33) EPS for the quarter, missing analysts' consensus estimates of ($1.16) by $0.17. The biopharmaceutical company earned $0.84 million during the quarter, compared to analyst estimates of $0.91 million. The firm's quarterly revenue was down 81.8% compared to the same quarter last year. During the same period in the previous year, the company earned ($1.38) EPS. What ETFs hold Cytokinetics' stock? ETFs with the largest weight of Cytokinetics (NASDAQ:CYTK) stock in their portfolio include Tema Cardiovascular and Metabolics ETF (HRTS), Fidelity Disruptive Medicine ETF (FMED), Principal Healthcare Innovators ETF (BTEC), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), VanEck Biotech ETF (BBH), BNY Mellon Innovators ETF (BKIV) and Harbor Health Care ETF (MEDI). What guidance has Cytokinetics issued on next quarter's earnings? Cytokinetics updated its FY 2024 earnings guidance on Tuesday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $3.0 million-$5.0 million, compared to the consensus revenue estimate of $28.5 million. What is Robert I. Blum's approval rating as Cytokinetics' CEO? 16 employees have rated Cytokinetics Chief Executive Officer Robert I. Blum on Glassdoor.com. Robert I. Blum has an approval rating of 64% among the company's employees. What other stocks do shareholders of Cytokinetics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Cytokinetics investors own include XOMA (XOMA), Arena Pharmaceuticals (ARNA), OncoSec Medical (ONCS), Novavax (NVAX), Amgen (AMGN), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), Dynavax Technologies (DVAX), TherapeuticsMD (TXMD) and Gilead Sciences (GILD). Who are Cytokinetics' major shareholders? Cytokinetics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Nationale Nederlanden Powszechne Towarzystwo Emerytalne S.A. (0.44%), Principal Financial Group Inc. (0.41%), Pinnacle Associates Ltd. (0.25%), Russell Investments Group Ltd. (0.23%), Swiss National Bank (0.17%) and BNP Paribas Financial Markets (0.16%). Insiders that own company stock include B Lynne Parshall, Ching Jaw, David Cragg, Edward M Md Kaye, Fady Ibraham Malik, John T Henderson, L Patrick Gage, Mark A Schlossberg, Muna Bhanji, Robert I Blum, Robert I Blum, Robert Wong, Sandford D Smith, Santo J Costa and Wendall Wierenga. View institutional ownership trends. How do I buy shares of Cytokinetics? Shares of CYTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:CYTK) was last updated on 5/10/2024 by MarketBeat.com Staff From Our PartnersThe ONE AI Stock to own now. (It’s not Nvidia.)Weiss Ratings[Webinar] A Deep Dive into Options Volatility: Skew & Relative ValueOICConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThis 1 Biotech Stock has been shocking the marketsHuge AlertsTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaHe Is Giving Away BitcoinCrypto Swap ProfitsGold Set to EXPLODE!Gold Safe ExchangeCharles Payne Demystifies OptionsUnstoppable Prosperity Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cytokinetics, Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
